These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anti-IgE for asthma in inner-city children. Pavord ID, Bush A. N Engl J Med; 2011 Jun 30; 364(26):2556-7; author reply 2557-8. PubMed ID: 21714664 [No Abstract] [Full Text] [Related]
4. Summaries for patients. Omalizumab therapy for patients with severe asthma. Ann Intern Med; 2011 May 03; 154(9):I28. PubMed ID: 21536934 [No Abstract] [Full Text] [Related]
5. Monitoring Allergic Patients on Omalizumab with Free and Total Serum IgE Measurements. Hamilton RG. J Allergy Clin Immunol Pract; 2016 May 03; 4(2):366-8. PubMed ID: 26968963 [No Abstract] [Full Text] [Related]
6. [Pneumology. Anti-IgE antibodies in the treatment of asthma]. Leuenberger P, Sauty A, Rochat T. Rev Med Suisse; 2007 Jan 10; 3(93):56-9. PubMed ID: 17354662 [Abstract] [Full Text] [Related]
7. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Chen H, Eisner MD, Haselkorn T, Trzaskoma B. Respir Med; 2013 Jan 10; 107(1):60-7. PubMed ID: 23083840 [Abstract] [Full Text] [Related]
8. [Programs for continuing medical education: A session; 7. Current topics of asthma treatment--anti-IgE therapy]. Adachi M, Tanaka A. Nihon Naika Gakkai Zasshi; 2012 Mar 10; 101(3):689-93. PubMed ID: 22620037 [No Abstract] [Full Text] [Related]
13. [Anti-IgE therapy in persistent allergic asthma]. Skiepko R, Zietkowski Z, Tomasiak-Łozowska MM, Bodzenta-Łukaszyk A. Przegl Lek; 2009 Feb 10; 66(3):141-4. PubMed ID: 19689039 [Abstract] [Full Text] [Related]
14. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE. Asai N, Ohkuni Y, Komatsu A, Matsunuma R, Nakashima K, Kaneko N. J Bras Pneumol; 2011 Feb 10; 37(4):567-70. PubMed ID: 21881749 [No Abstract] [Full Text] [Related]
15. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD, Omalizumab 011 International Study Group. Clin Exp Allergy; 2004 Apr 10; 34(4):632-8. PubMed ID: 15080818 [Abstract] [Full Text] [Related]
16. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, Leo J, Peckitt C, Maykut R, Peachey G. Allergy; 2011 May 10; 66(5):671-8. PubMed ID: 21255035 [Abstract] [Full Text] [Related]
17. Discrimination against children with severe allergies. Warner JO. Pediatr Allergy Immunol; 2008 Dec 10; 19(8):671-2. PubMed ID: 19076563 [No Abstract] [Full Text] [Related]
18. Omalizumab treatment in a child with severe asthma and multiple steroid-induced morbidities. Rizk C, Ring A, Santucci S, MacLusky I, Karsh J, Yang WH. Ann Allergy Asthma Immunol; 2012 Sep 10; 109(3):222-3. PubMed ID: 22920081 [No Abstract] [Full Text] [Related]
19. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta-Lukaszyk A. Int Arch Allergy Immunol; 2011 Sep 10; 154(1):25-32. PubMed ID: 20664274 [Abstract] [Full Text] [Related]
20. [Treatment of an asthmatic patient on dialysis and awaiting transplantation with anti-IgE]. Lafourcade MP, Martin M, Yver L. Rev Mal Respir; 2008 Sep 10; 25(7):857-60. PubMed ID: 18946412 [Abstract] [Full Text] [Related] Page: [Next] [New Search]